Tandem Diabetes Care reports developments in automated insulin delivery and diabetes technology. The company manufactures and sells pump systems including Tandem Mobi and the t:slim X2 insulin pump, both powered by Control-IQ+ advanced hybrid closed-loop technology. News commonly covers FDA clearances, pump and mobile-app compatibility, continuous glucose monitoring integrations, and product portfolio updates for people with diabetes.
Company updates also address quarterly and annual operating results, worldwide and U.S. sales trends, pump shipments, gross margin, financial guidance, reimbursement-model changes, investor conference presentations, and capital actions such as convertible debt financing.
Tandem Diabetes Care (Nasdaq: TNDM) will release its first quarter 2026 financial and operating results after market close on May 7, 2026. A conference call and simultaneous webcast are scheduled for 4:30 PM ET (1:30 PM PT) that day.
According to the company, the live webcast and an archive (available for 30 days) will be accessible via the company Investor Center in the "Events & Presentations" section; phone access requires registration to receive dial-in details and a personal PIN.
Tandem Diabetes Care (Nasdaq: TNDM) announced that the Tandem Mobi automated insulin delivery system now pairs with compatible Android smartphones in the U.S. via the Tandem Mobi mobile app. The Android app received FDA clearance in November 2025 and had a limited release in December 2025.
The app is available on Google Play for compatible devices, including Google Pixel 6–10 and Samsung Galaxy S21–S25, expanding patient choice and connected-care accessibility.
Tandem Diabetes Care (NASDAQ: TNDM) priced an upsized private placement of $265.0 million 0.00% convertible senior notes due March 15, 2032, expected to close February 27, 2026. Net proceeds are estimated at $256.7 million (or $290.7 million if option exercised).
The notes convert at 27.0362 shares per $1,000 principal (≈ $36.99 per share), a ~37.5% premium to the Feb 24, 2026 share price; Tandem entered capped call transactions with an initial cap price of $47.075.
Tandem Diabetes Care (NASDAQ: TNDM) intends to sell $200.0 million aggregate principal amount of Convertible Senior Notes due 2032 in a private placement, with an option to sell an additional $30.0 million. Notes are unsecured, interest-bearing, convertible into cash, stock, or both.
Proceeds are expected to pay capped call transaction costs and for general corporate purposes, possibly including acquisitions, working capital, operating expenses and capital expenditures.
Tandem Diabetes Care (Nasdaq: TNDM) reported record Q4 sales of $290.4M and full‑year 2025 worldwide sales of $1.015B. Q4 gross margin reached 58%; full‑year gross margin was 54%. Full‑year shipments exceeded 126,000 pumps. Q4 operating income was $8.3M; full‑year GAAP net loss was $204.7M. Adjusted EBITDA for 2025 was a negative $46.1M. For 2026 the company guided sales of $1.065B–$1.085B, ~10%–11% shipment growth, gross margin ~56%–57%, and adjusted EBITDA margin ~5%–6%, while noting pay‑as‑you‑go and direct transition headwinds.
Tandem Diabetes Care (Nasdaq: TNDM) announced management will present company updates at three investor conferences in Feb–Mar 2026: Citi Unplugged MedTech on Feb 26, 2026 at 1:45pm ET, TD Cowen on Mar 4, 2026 at 9:10am ET, and Oppenheimer on Mar 18, 2026 at 1:20pm ET.
All presentations will be webcast live and archived for 30 days on the company's Investor Center under "Events & Presentations."
Tandem Diabetes Care (Nasdaq: TNDM) will release its fourth quarter and full year 2025 financial results after market close on Thursday, February 19, 2026. The company will host a conference call and simultaneous webcast the same day at 4:30 PM ET (1:30 PM PT) to discuss financial and operating results.
Investors can access the live webcast and an archived recording (available for 30 days) via Tandem Diabetes Care’s Investor Center under “Events & Presentations.” Telephone access and dial-in details are provided after registration through the company’s listed registration link.
Tandem Diabetes Care (Nasdaq: TNDM) announced on December 18, 2025 that the Tandem t:slim mobile app is now available in Canada for Android and iOS. The app lets eligible t:slim X2 users (pump version 7.8.1+) deliver and cancel boluses from a paired smartphone, view 24-hour glucose trends, pump status, basal/bolus deliveries and suspensions, and receive pump alerts. Data can be uploaded wirelessly to the cloud-based Tandem Source platform. The t:slim X2 pump continues to operate independently, and uploads are not real-time.
Tandem Diabetes Care (Nasdaq: TNDM) announced the appointment of Sandra Beaver to its board of directors effective November 7, 2025. Ms. Beaver joins as an independent director and will serve on the board’s Audit Committee and Cybersecurity and Data Oversight Committee. She brings more than 20 years of strategic and operational finance experience across healthcare, medical devices, enterprise technology, gaming and manufacturing. Ms. Beaver is currently CFO at Lyra Health (since June 2025) and previously served three years as CFO at Evolus, with prior senior finance roles at Experian and IGT. Her credentials include a Bachelor of Business Administration from University of Massachusetts and a Professional Designation in Relational Database Design from UCLA.
Tandem Diabetes Care (Nasdaq: TNDM) announced FDA clearance of the Android version of the Tandem Mobi mobile app, expanding compatibility to Android smartphones and extending its connected-care ecosystem.
Key facts: the app pairs with the Tandem Mobi automated insulin delivery system powered by Control-IQ+, cites outcomes including 79% time in range and 90% overnight time in range, and will begin a limited release in December 2025 with commercial availability in early 2026. Compatible devices slated to include Google Pixel 6–10 and Samsung Galaxy S21–S25; a full compatibility list will be published before launch.